Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Melanoma tissue samples from a clinical trial: no treatment vs. post-temsirolimus alone vs. post-combination temsirolimus and bevacizumab

ABSTRACT: To determine if treatment with a combined therapeutic regimen, which resulted in clinical benefit in a subset of patients in a clinical trial, alters miRNA expression in a way that may be used to guide treatment with these agents and to identify miRNAs that may be involved in the mechanism of action of this regimen

ORGANISM(S): Merkel cell polyomavirus Rattus norvegicus Human gammaherpesvirus 8 Mus musculus JC polyomavirus Betapolyomavirus macacae Homo sapiens Murid gammaherpesvirus 4 Human immunodeficiency virus 1 Human betaherpesvirus 5 Human alphaherpesvirus 2 Betapolyomavirus hominis Human alphaherpesvirus 1 human gammaherpesvirus 4 Mus musculus cytomegalovirus 2 Murid betaherpesvirus 1

PROVIDER: GSE37131 | GEO | 2013/03/08

SECONDARY ACCESSION(S): PRJNA158407

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Melanoma tissue samples from a clinical trial: no treatment vs. post-temsirolimus alone vs. post-combination temsirolimus and bevacizumab

Project description:To determine if treatment with a combined therapeutic regimen, which resulted in clinical benefit in a subset of patients in a clinical trial, alters miRNA expression in a way that may be used to guide treatment with these agents and to identify miRNAs that may be involved in the mechanism of action of this regimen Three-condition experiment, untreated tissue, post-temsirolimus alone treatment, post combination-treatment tissue. 33 total samples, including 5 samples resubmitted for quality control.

2013-03-08 | E-GEOD-37131 | biostudies-arrayexpress

Melanoma tissue samples from a clinical trial: no treatment vs. post-temsirolimus alone vs. post-combination temsirolimus and bevacizumab

| S-ECPF-GEOD-37131 | biostudies-other

The NEWEST trial

Project description:The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological activity of fulvestrant 500 mg vs 250 mg in the neoadjuvant setting. In this multi-centre phase II study, post-menopausal women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumours were randomised to receive neoadjuvant treatment with either dose of fulvestrant for 16 weeks before surgery. Tumour core biopsies were obtained at baseline, 4 weeks and at surgery for assessment of changes in biomarker expression. Tumour volumes were measured by 3-D ultrasound at the same timepoints. In this trial, the percentage of patients who showed a reduction in tumour volume or stabilisation of disease (using RECIST criteria) after treatment with fulvestrant 500 mg was 36% (26 out of 69 patients). Therefore, within a population of endocrine-therapy naive patients whose tumours were confirmed as being ER-positive at the time of study entry, there is a subgroup who gained particular clinical benefit from fulvestrant treatment. These clinical response data together with the availability of biological response information and frozen tumour tissue from participants makes the NEWEST trial an attractive setting in which to investigate the potential of new markers of response to fulvestrant. 42 samples

2014-01-08 | E-GEOD-48905 | biostudies-arrayexpress

Expression data from 36 KRAS-mutant lung adenocarcinomas from the BATTLE-2 clinical trial.

Project description:In this dataset, we include expression data from 36 KRAS-mutant lung adenocarcinomas from Stage 1 of the BATTLE-2 trial, reflecting patients whose disease has relapsed or progresses following at least one front-line metastatic chemotherapy regimen. Tumor biopsy was performed following informed consent and prior to randomisation to one of the four possible treatment arms.

2015-10-01 | GSE61913 | GEO

The NEWEST trial

2014-01-08 | GSE48905 | GEO

Modulation of profibrotic pathways in systemic sclerosis skin from focuSSced trial with treatment

Project description:Previous microarray analysis of skin biopsies from patients enrolled in the FaSScinate clinical trial revealed pathways modulated by treatment and associated with aggressive disease course. To further our understanding of these pathways, we performed RNA-seq on patients enrolled in the FocuSSced clinical trial to confirm the previous finding and explore new treatment modulated pathways.

2023-07-26 | GSE231692 | GEO

Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial.

Project description:Purpose:To evaluate the efficacy of three intravitreal bevacizumab (IVB) injections versus the same combined with 2% of topical dorzolamide in the treatment of diabetic macular edema (DME). Methods:In this randomized double-masked clinical trial, 32 eyes of 16 treatment-naive patients with bilateral DME were enrolled. The eyes were randomly assigned to receive three monthly injections of IVB (1.25?mg) plus topical dorzolamide 2% twice daily or IVB (1.25?mg) plus topical artificial tear twice daily. Best-corrected visual acuity (BCVA) was the primary outcome of the study followed by the central macular thickness (CMT) and central macular volume (CMV) as the secondary outcomes. Results:Mean BCVA changes were insignificant in both groups. It changed from 0.21?±?0.08 logMAR at baseline to 0.23?±?0.09 (P=0.24) in the combination group and from 0.18?±?0.09 logMAR to 0.21?±?0.09 (P=0.11) in the IVB alone group, at 3 months, respectively. Changes in mean CMT and CMV were significant in both groups. However, the difference between the groups was not significant at all the visits. In the study, no major ocular complication or systemic side effects were noted regarding IVB or topical dorzolamide. Conclusion:This randomized contralateral clinical trial demonstrated that adjuvant topical dorzolamide with IVB injection had no additional effects on IVB in the treatment of DME over a three-month course. This trial is registered with the Iranian Registry of Clinical Trials under the registration code IRCT20131229015975N5.

| S-EPMC6988687 | biostudies-literature

Transcriptomic analysis of the NA-PHER2 clinical trial

Project description:We performed whole transcriptome RNA sequencing on serial tumour biopsies collected at baseline, Day 14, and after completion of all neoadjuvant therapy from the NA-PHER2 trial. Patients received neoadjuvant treatment with the combined regimen of trastuzumab, pertuzumab, palbociclib with or without addition of fulvestrant. Transcriptomic profiles were generated from 143 samples (Baseline n = 53, Day 14 n = 49, Surgery n = 41) corresponding to 55 of the 58 patients enrolled in NA-PHER2 trial (94.8%). RNA sequencing was performed on total RNA samples derived from formalin-fixed, paraffin-embedded (FFPE) tissue sections. RNA-Seq libraries were produced using NEBNext® Ultra™ II Directional RNA Library Prep Kit. The capture was then performed on cDNA libraries with the Twist Human Core Exome Enrichment System according to supplier recommendations (Twist Bioscience). The obtained eluted-enriched DNA samples was then sequenced on an Illumina NovaSeq as paired-end 100bp reads.

2024-10-31 | E-MTAB-14448 | biostudies-arrayexpress

Trial

Project description:Trial Trial

| PRJEB7892 | ENA

Clinical Trial Sequencing Project (CTSP)

Project description:Clinical Trial Sequencing Project (CTSP)

| PRJNA331220 | ENA